Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. News about FATE centers on its off-the-shelf CAR T-cell and NK-cell product candidates, including FT819, FT836 and FT839, and on clinical or preclinical data presented at medical and cell-therapy meetings.
Recurring updates cover FT819 in systemic lupus erythematosus and other autoimmune diseases, next-generation CAR T programs for hematological malignancies and solid tumors, manufacturing and FDA CMC interactions, Regenerative Medicine Advanced Therapy designation, investor-conference participation, financial results, and Nasdaq employee inducement equity awards.
Fate Therapeutics (NASDAQ: FATE) announced the retirement of Amir Nashat from its board of directors, marking a significant leadership change. Nashat had been a board member since the company's inception in 2007. Robert Hershberg, with extensive experience in immuno-oncology and business development, has been appointed as a new board member. He previously held executive roles at Celgene and VentiRx Pharmaceuticals. The company is focused on advancing its iPSC-derived cell therapies aimed at treating cancer and immune disorders.
Fate Therapeutics (NASDAQ: FATE) will host a conference call on May 11, 2020, at 5:00 p.m. ET to discuss its first quarter 2020 financial results and provide a corporate update. Participants can join by calling 877-303-6235 (domestic) or 631-291-4837 (international), using conference ID 8623509. The event will also be available via a live audio webcast, which can be accessed on the company’s website under "Events & Presentations." Fate Therapeutics focuses on developing programmed cellular immunotherapies for cancer and immune disorders using its proprietary iPSC product platform.